News
Why Eli Lilly (LLY) Stock Is Nosediving
Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) fell 11% in the afternoon session after the company reported weak first quarter 2025 results which included an EPS miss due to lower-than-expected profitability and full-year EPS guidance that missed significantly.
Eli Lilly on Thursday posted better-than-expected quarterly results, but CVS Health's decision to drop the company's obesity ...
Eli Lilly (LLY) is among the list of large-cap pharmaceutical companies that are awaiting the Trump administration's word on ...
Eli Lilly’s stock wobbled Thursday after a looming coverage hit was detailed for its blockbuster weight-loss drug Zepbound.
Eli Lilly on Thursday downplayed CVS Health's decision to drop the company's obesity drug Zepbound from some lists of ...
But Eli Lilly CEO David Ricks waved off the deal Thursday, telling Yahoo Finance in an interview that the company is focused ...
Starting on July 1, Wegovy will become the preferred GLP-1 for obesity treatment on CVS Caremark’s largest commercial ...
Ricks said reshoring manufacturing capacity for older essential medicines is "a valid thing," adding that Eli Lilly is "happy ...
We recently published a list of How Did Jim Cramer’s 12 Bold Predictions Play Out?. In this article, we are going to take a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback